Why the study?
Do lecithin-coated microcrystal formulations of dantrolene effectively treat malignant hyperthermia without adverse pulmonary effects compared to standard dantrolene in animal models?
Do lecithin-coated microcrystal formulations of dantrolene effectively treat malignant hyperthermia without adverse pulmonary effects compared to standard dantrolene in animal models?
Lecithin-coated microcrystal neutral dantrolene (MC-D) shows similar efficacy to standard dantrolene for malignant hyperthermia without causing marked pulmonary hypertension, suggesting potential for improved treatment.
No takes yet. Share an insight, caveat, or question.
MC-D merits human safety trials before any clinical use; leaves open whether reduced pulmonary hypertension translates beyond swine MH models.
Karan et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: